Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:CALC NASDAQ:MTEX NYSEAMERICAN:OGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.80-0.3%$0.84$0.55▼$2.22$9.90M1.511.24 million shs7,080 shsCALCCalciMedica$1.12+8.3%$0.73$0.46▼$7.20$17.62M0.971.24 million shs618,157 shsMTEXMannatech$5.21+0.8%$5.08$3.80▼$12.45$10.06M0.7224,770 shs604 shsOGENOragenics$0.60+2.5%$0.60$0.50▼$1.58$2.68M1.27290,929 shs8,734 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-2.04%-3.10%-10.12%+14.00%-52.53%CALCCalciMedica+4.36%+28.22%+26.07%+75.11%-35.63%MTEXMannatech+0.77%-2.98%-8.60%-17.56%-44.28%OGENOragenics-1.59%-1.26%-4.16%+5.56%-84.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.80-0.3%$0.84$0.55▼$2.22$9.90M1.511.24 million shs7,080 shsCALCCalciMedica$1.12+8.3%$0.73$0.46▼$7.20$17.62M0.971.24 million shs618,157 shsMTEXMannatech$5.21+0.8%$5.08$3.80▼$12.45$10.06M0.7224,770 shs604 shsOGENOragenics$0.60+2.5%$0.60$0.50▼$1.58$2.68M1.27290,929 shs8,734 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-2.04%-3.10%-10.12%+14.00%-52.53%CALCCalciMedica+4.36%+28.22%+26.07%+75.11%-35.63%MTEXMannatech+0.77%-2.98%-8.60%-17.56%-44.28%OGENOragenics-1.59%-1.26%-4.16%+5.56%-84.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07406.88% UpsideCALCCalciMedica 2.00Hold$10.00870.87% UpsideMTEXMannatech 1.00SellN/AN/AOGENOragenics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OGEN, CALC, APRE, and MTEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K34.25N/AN/A$1.52 per share0.53CALCCalciMedicaN/AN/AN/AN/A($0.46) per shareN/AMTEXMannatech$108.04M0.09N/AN/A($2.75) per share-1.89OGENOragenics$40K65.46N/AN/A$1.94 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)CALCCalciMedica-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)MTEXMannatech-$15.21M-$6.71N/AN/AN/A-11.97%-2,383.34%-40.24%N/AOGENOragenics-$9.84M-$21.42N/AN/AN/AN/A-177.32%-121.29%N/ALatest OGEN, CALC, APRE, and MTEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q4 2025MTEXMannatechN/A$0.49N/A$0.49N/A$24.92 million5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A5/8/2026Q1 2026OGENOragenicsN/A-$0.51N/A-$0.51N/AN/A4/15/2026Q4 2025MTEXMannatechN/A-$5.94N/A-$5.94N/A$26.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/AMTEXMannatechN/AN/A-100.00%N/AN/AOGENOragenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92CALCCalciMedicaN/A1.611.61MTEXMannatech0.481.090.59OGENOragenicsN/A5.735.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CALCCalciMedicaN/AMTEXMannatech12.98%OGENOragenics18.71%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics10.49%CALCCalciMedica41.55%MTEXMannatech41.50%OGENOragenics16.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataCALCCalciMedica3015.80 million9.23 millionNo DataMTEXMannatech2501.93 million1.13 millionNot OptionableOGENOragenics54.51 million3.79 millionN/AOGEN, CALC, APRE, and MTEX HeadlinesRecent News About These CompaniesOragenics (NYSEAMERICAN:OGEN) Trading 2.6% Higher - Here's WhyJune 27, 2026 | americanbankingnews.comOragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21May 19, 2026 | finance.yahoo.comOragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21May 19, 2026 | globenewswire.comORAGENICS PROVIDES INVESTOR UPDATEMay 18, 2026 | globenewswire.comOragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic InflammationMay 7, 2026 | globenewswire.comOragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.May 5, 2026 | globenewswire.comOragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryApril 20, 2026 | finance.yahoo.comOragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryApril 13, 2026 | globenewswire.comOragenics, Inc. Receives Unqualified Audit Opinion with Going Concern Explanatory Paragraph in Latest Annual ReportMarch 25, 2026 | quiverquant.comQOragenics, Inc. Receives Audit Opinion with Going Concern ExplanationMarch 25, 2026 | globenewswire.comORAGENICS FILES ANNUAL REPORT ON FORM 10-KMarch 17, 2026 | finance.yahoo.comOragenics, Inc.: Oragenics Initiates Phase Iia Clinical Trial Site ActivationMarch 12, 2026 | finanznachrichten.deORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATIONMarch 12, 2026 | globenewswire.comORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTIONMarch 11, 2026 | globenewswire.comOragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in AustraliaMarch 10, 2026 | globenewswire.comOragenics previews targeted milestones for 2026February 10, 2026 | finance.yahoo.comOragenics, Inc.: Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury TherapyFebruary 9, 2026 | finanznachrichten.deOragenics, Inc. Prepares for Phase 2 Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain InjuryFebruary 9, 2026 | quiverquant.comQOragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury TherapyFebruary 9, 2026 | globenewswire.comOragenics partners with Duck Flats Pharma to support FDA IND trial designFebruary 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOGEN, CALC, APRE, and MTEX Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.80 0.00 (-0.29%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.CalciMedica NASDAQ:CALC$1.12 +0.09 (+8.25%) As of 11:40 AM Eastern This is a fair market value price provided by Massive. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Mannatech NASDAQ:MTEX$5.21 +0.04 (+0.77%) As of 09:45 AM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.Oragenics NYSEAMERICAN:OGEN$0.60 +0.01 (+2.48%) As of 11:40 AM Eastern This is a fair market value price provided by Massive. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Charts That Could Change the Course of Summer Trading Short Squeeze Alert—Moderna Stock Surges on New Strategy These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Could Apple's China Play Be the Answer to Its Memory Pressure Problem? Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
